Duan, L.; Calhoun, S.; Perez, R.E.; Macias, V.; Mir, F.; Pergande, M.R.; Gattuso, P.; Borgia, J.A.; Maki, C.G.
Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers 2022, 14, 739.
https://doi.org/10.3390/cancers14030739
AMA Style
Duan L, Calhoun S, Perez RE, Macias V, Mir F, Pergande MR, Gattuso P, Borgia JA, Maki CG.
Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers. 2022; 14(3):739.
https://doi.org/10.3390/cancers14030739
Chicago/Turabian Style
Duan, Lei, Sarah Calhoun, Ricardo E. Perez, Virgilia Macias, Fatima Mir, Melissa R. Pergande, Paolo Gattuso, Jeffrey A. Borgia, and Carl G. Maki.
2022. "Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer" Cancers 14, no. 3: 739.
https://doi.org/10.3390/cancers14030739
APA Style
Duan, L., Calhoun, S., Perez, R. E., Macias, V., Mir, F., Pergande, M. R., Gattuso, P., Borgia, J. A., & Maki, C. G.
(2022). Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers, 14(3), 739.
https://doi.org/10.3390/cancers14030739